Skip to content
type1.science

Aspect Biosystems bioprinted islet tissue (ex-Novo Nordisk platform)

Aspect Biosystems (platform and hypoimmune/stem-cell-islet technologies acquired from Novo Nordisk, January 2026)

A pharma retreat rehomed as a startup's flagship. Rodent data only.

A 3D-bioprinted implant of stem-cell-derived islet clusters wrapped in an immune-protective shell, combined with hypoimmune cell engineering acquired from Novo Nordisk in January 2026. The aim is an implant that controls blood sugar with no anti-rejection drugs. Nothing has been tested in a human: there is no IND and no registered trial, and the only disclosed efficacy data are from rats.

Years awayPreclinicalstem-cellisletgene-editinghypoimmuneimmune-evasionencapsulationbioprintingallogeneiccombinationcell-therapyOfficial site ↗

The scorecard

Efficacy20

The only disclosed efficacy data for the islet implant is a 2022 ADA conference poster in which bioprinted implants restored normoglycemia in diabetic rats. Those were *rat* islets, not the stem-cell-derived human islets the product is meant to use, and they were not hypoimmune-edited. No human has received this therapy, and no efficacy data of any kind have been disclosed for the combined product.[3]

Immunosuppression-free45

The design is genuinely drug-free by construction — an immune-protective biomaterial shell plus hypoimmune gene editing, with no chronic systemic anti-rejection drug anywhere in it. But that is a design, not a result. The rodent work that supports the "without immune suppression" claim used allogeneic rat islets in streptozotocin-diabetic rats: a chemical diabetes model with no autoimmunity in it at all, so it tested rejection and never touched the autoimmune attack that actually causes T1D. The hypoimmune technology was acquired only in January 2026 and has never been publicly shown combined with the bioprinted implant. Scored well below Sana (75), which is the only programme on earth with human drug-free evidence.[3]

Maturity12

Among the least mature records in this pillar. There is no IND, no clinical trial application and no registered trial — a ClinicalTrials.gov sponsor query for Aspect Biosystems returns zero studies. Aspect's own pipeline page declines to assign the type 1 diabetes programme a development stage at all, listing it as "Undisclosed" while its adrenal programme is marked "Preclinical". No first-in-human timeline has been given.[6]

Safety45

No human safety data exist. Two structural points cut in its favour: a printed, macro-scale tissue is retrievable if it misbehaves, and avoiding chronic immunosuppression avoids that drug class's real toxicity. Against it: hypoimmune editing carries the field's standing concerns about NK-cell control and tumour surveillance in cells deliberately hidden from the immune system, and there is no clinical safety database whatsoever to weigh them against.[5]

Durability18

Rodent-only, and short. The 2022 poster reports normoglycemia beyond 90 days in immunodeficient rats and beyond 30 days in immunocompetent rats. Thirty days in a rat is a very thin basis for a therapy that would need to last decades in a person, and no longer or human durability data have been disclosed in the four years since.[3]

Eligibility breadth55

Potential only. If a stem-cell-derived, off-the-shelf implant ever worked without immunosuppression it could in principle reach the broad T1D population rather than only the most severe cases — that is the whole point of the design. But no trial has enrolled anyone, so no eligibility criteria exist to assess.[1]

Immunosuppression-free is scored here, as it is for cell replacement and encapsulation — freeing a therapy from lifelong anti-rejection drugs is the central barrier this whole pillar is trying to clear, so an approach that achieves it must be able to earn credit for it. It is scored on evidence, not intent: a platform designed to avoid immunosuppression but never yet tested at a therapeutic dose scores on what it has shown. Approaches that transplant nothing (in-vivo gene therapy, reprogramming) need no anti-rejection drugs by construction, but they still face the original autoimmune attack — that unresolved risk belongs in this score, not hidden by it.

Editor’s take

The structural story matters more than the science story, because the science story is four years old and about rats. In October 2025 Novo Nordisk closed its cell therapy unit, cut nearly all 250 staff and killed its own T1D programme. In January 2026 it handed the stem-cell-islet and hypoimmune platforms to Aspect Biosystems — while keeping equity, an option to re-enter later-stage development, and royalties if it ever pays off. Both companies call it "a new phase of their partnership". It is a major pharma retreat from T1D cell therapy with the risk and the cost transferred to a smaller company and the upside retained. Aspect gains a genuinely strong platform it could not have built alone, and its drug-free design is honest — no chronic anti-rejection drug is hiding anywhere in it. But the field lost its deepest pockets, and what Aspect has to show is a 2022 conference poster in which rat islets, in a shell, in chemically-diabetic rats with no autoimmunity, held blood sugar for thirty days. The hypoimmune edits and the printed implant have never been publicly shown working together, in any species. Ambition is not evidence, and we do not rank it as if it were.

The full picture

Start with how this programme got here, because it is the most informative thing about it. In October 2025 Novo Nordisk shut its cell therapy unit, laying off nearly all 250 people in it and pulling the plug on its type 1 diabetes programme.1 Three months later, on 20 January 2026, Novo handed the wreckage to a partner: Aspect Biosystems, a Vancouver bioprinting company, acquired rights to Novo's stem-cell-derived islet and hypoimmune cell engineering technologies, along with select Novo cell-therapy research, development and manufacturing staff and capabilities from the United States and Denmark.2

The press release calls this "a new phase of their partnership."2 Read it as what it is. One of the two or three best-capitalised drug companies on earth spent years and hundreds of millions trying to build a cell-based cure for T1D, concluded it did not want to finish, and found a smaller company to carry the assets — while keeping an equity stake, an option to re-enter later-stage development, and royalties if it ever works.2 Novo has offloaded the cost and the risk and retained the upside. That is a retreat, and the trade press reported it as one.1 It is not bad news for Aspect, which gets a real technology stack it could not have built alone. It is bad news for the field: the deep pockets left the room.

What the therapy actually is. Aspect's approach is a "cage and cloak" combination — and it is the combination, not any single piece, that defines it:

  • Bioprinting. Aspect's microfluidic 3D printer lays down fibres with a core-and-shell structure: insulin-producing islet clusters in the core, an immune-protective biomaterial in the shell.3 The result is a macro-scale printed tissue that can be implanted — and, importantly, retrieved.
  • Stem-cell-derived islets (from Novo) — the potentially unlimited cell supply that removes the dependence on deceased donors.2
  • Hypoimmune cell engineering (from Novo) — gene edits intended to make the cells themselves invisible to the immune system, the same family of approach Sana and CRISPR Therapeutics are pursuing.2

The stated goal is "an islet replacement therapy for type 1 diabetes designed to restore blood glucose control without the need for chronic immune suppression."2 That is a worthy goal. It is also, today, only a goal.

What has actually been shown. Very little, and not recently. The only disclosed efficacy data for the islet programme is a conference poster from 2022 — not a peer-reviewed paper — presented at the ADA's 82nd Scientific Sessions.4 In it, bioprinted core-shell implants restored normal blood sugar in diabetic rats: more than 90 days in immunodeficient rats, and more than 30 days in immunocompetent rats, with no immune cells found penetrating the shell.4 Aspect's own announcement of the poster quotes its CEO on the promise of "a cell-based therapy that doesn't require chronic immune suppression."5

Three things about that result matter more than the headline, and the headline is what usually travels:

  1. Those were rat islets, in rats. Not the stem-cell-derived human islets the actual product is supposed to contain.4
  2. Those implants were not hypoimmune-edited. Whatever immune protection they had came from the biomaterial shell. The hypoimmune technology arrived from Novo in January 2026 — four years later — and Aspect has published nothing showing the two combined.24
  3. The diabetes was chemical, not autoimmune. Streptozotocin poisons beta cells; it does not give a rat type 1 diabetes. So the model tested whether the shell could stop rejection of foreign islets. It contained no autoimmunity whatsoever, and therefore said nothing about the recurring autoimmune attack that destroyed the person's beta cells in the first place — the problem that has defeated every drug-free approach so far.4

"Normalize blood glucose control in diabetic rat models without immune suppression" is a true sentence about rats. It is not evidence about people.

Where it stands. Nowhere near a clinic. As of 15 July 2026 there is no IND, no clinical trial application, and no registered trial — a ClinicalTrials.gov sponsor query for Aspect Biosystems returns zero studies, in any indication.6 Aspect's own pipeline page is the tell: its adrenal-insufficiency programme is labelled "Preclinical," while the type 1 diabetes programme's development stage is listed as "Undisclosed."7 A company that will happily call one programme preclinical and will not put a stage on another is telling you something. No first-in-human timeline has been announced.

Money is not the constraint: the Canadian government has put substantial funding behind Aspect's biomanufacturing build-out, and the Novo deal brings equity and research funding on top.82 Capital, a technology stack, and a real manufacturing plan are all present. Human data are entirely absent.

How to hold this record. Aspect is a legitimate, well-funded company with an unusually complete platform — bioprinting, cells, gene engineering and biomaterials under one roof — and a design that, unlike most of the field, does not smuggle a chronic anti-rejection drug in through the back door. If you are going to attempt a drug-free cure, this is a sane way to attempt it. But every claim attached to it is currently a claim about intentions and rodents. Set it against the only human benchmark that exists — one man in Sweden, 14 months, no immunosuppression, still on insulin because the dose was deliberately too small to treat him — and the honest ranking follows: this is one of the least mature records on the site, and it should stay that way until somebody publishes data from an animal that has autoimmunity, and then from a person.

References

References

  1. BioSpace. After cell therapy retreat, Novo offloads technologies in deepened Aspect pact — Novo's October 2025 exit from cell therapy "claimed the jobs of nearly all 250 of the company's cell therapy employees" and "pulled the plug on its type 1 diabetes program"; the 2023 Aspect partnership was $75M upfront plus up to $650M in milestones. BioSpace (2026). https://www.biospace.com/deals/after-cell-therapy-retreat-novo-offloads-technologies-in-deepened-aspect-pact ↩ ↩2

  2. Aspect Biosystems. Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes — Aspect acquires rights to stem cell-derived islet cell and hypoimmune cell engineering technologies; Novo makes an additional equity investment, provides research funding, retains defined rights to later-stage development and commercialisation, and is eligible for royalties and milestones. Aspect Biosystems (20 January 2026). https://www.aspectbiosystems.com/news-resources/aspect-biosystems-novo-nordisk-enter-new-phase-of-partnership-to-develop-curative-medicines-for-diabetes ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8

  3. Aspect Biosystems. Pipeline of bioprinted tissue therapeutics — the T1D candidate is described as stem cell islet clusters encapsulated within immune-protective materials. Aspect Biosystems (accessed 15 July 2026). https://aspectbiosystems.com/programs ↩

  4. Russo V, Jalili R, Yu Y, et al. 816-P: Bioprinted allogeneic islet-containing implants normalize blood glucose control in diabetic rat models without immune suppression. Diabetes 2022;71(Supplement_1) — ADA 82nd Scientific Sessions. Conference abstract, not peer-reviewed. Allogeneic rat islets; >90 days normoglycemia in STZ-diabetic immunodeficient rats, >30 days in immunocompetent rats. https://diabetesjournals.org/diabetes/article/71/Supplement_1/816-P/145334/816-P-Bioprinted-Allogeneic-Islet-Containing ↩ ↩2 ↩3 ↩4 ↩5

  5. Aspect Biosystems. Aspect Biosystems to present on pancreatic tissue therapeutic at American Diabetes Association 82nd Scientific Sessions. Aspect Biosystems (2022). https://www.aspectbiosystems.com/news-resources/to-present-on-pancreatic-tissue-therapeutic-at-ada-2022 ↩

  6. ClinicalTrials.gov. Sponsor query for Aspect Biosystems returns totalCount 0 — no registered trials in any indication. U.S. National Library of Medicine (run 15 July 2026). https://clinicaltrials.gov/api/v2/studies?query.spons=Aspect+Biosystems&format=json&countTotal=true ↩

  7. Aspect Biosystems. Programs — type 1 diabetes programme stage listed as "Undisclosed"; the rare endocrine (primary adrenal insufficiency) programme is listed as "Preclinical". Aspect Biosystems (accessed 15 July 2026). https://aspectbiosystems.com/programs ↩

  8. Pharmaceutical Technology. Aspect wins $72.75m from Canadian government for bioprinted pipeline — funding toward a $200m multi-year project to advance clinical biomanufacturing; notes the Novo collaboration "has so far produced a preclinical pancreatic tissue candidate for type 1 diabetes". Pharmaceutical Technology. https://www.pharmaceutical-technology.com/news/aspect-wins-72-75m-from-canadian-government-for-bioprinted-pipeline/ ↩

Coming soon

ETA · No IND, no clinical trial application and no registered trial as of July 2026, and no public first-in-human timeline. Aspect's own pipeline page will not assign the programme a development stage. Realistically years from a human ever receiving this

  • →Any disclosed data on the combined product — stem-cell-derived human islets, hypoimmune-edited, inside the bioprinted implant. Nothing of the kind has been shown publicly · not announced
  • →An IND or clinical trial application — the milestone that would put this in the clinic · not announced
  • →Efficacy data in a model that actually contains autoimmunity, rather than chemically-induced (STZ) diabetes · not announced

Sources

  1. [1]Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes · manufacturer · 2026-01-20 — Aspect acquires "rights to stem cell-derived islet cell and hypoimmune cell engineering technologies" from Novo Nordisk, plus select Novo cell-therapy R&D and manufacturing capabilities from the US and Denmark. Novo makes an additional equity investment, provides research funding, and keeps defined rights to later-stage development plus royalties and milestones. States a goal — "an islet replacement therapy for type 1 diabetes designed to restore blood glucose control without the need for chronic immune suppression" — and discloses no data, no stage and no timeline.
  2. [2]After Cell Therapy Retreat, Novo Offloads Technologies in Deepened Aspect Pact · news — Frames the deal as Novo offloading assets after its October 2025 exit from cell therapy, which "claimed the jobs of nearly all 250 of the company's cell therapy employees" and "pulled the plug on its type 1 diabetes program". The 2023 partnership was $75M upfront plus up to $650M in milestones; terms of the 2026 deal were not disclosed.
  3. [3]"816-P: Bioprinted Allogeneic Islet-Containing Implants Normalize Blood Glucose Control in Diabetic Rat Models without Immune Suppression" · conference · 2022-06-01 — Russo V, Jalili R, … Kieffer TJ, Wadsworth S. Diabetes 2022;71(Suppl 1), ADA 82nd Scientific Sessions. A conference abstract, not peer-reviewed. Reaggregated allogeneic *rat* islets in a bioprinted core-shell fibre re-established normoglycemia >90 days in STZ-diabetic immunodeficient rats and >30 days in immunocompetent rats. STZ diabetes is chemically induced — the model contains no autoimmunity. This remains the only disclosed efficacy data for the islet programme.
  4. [4]Aspect Biosystems to Present on Pancreatic Tissue Therapeutic at American Diabetes Association 82nd Scientific Sessions · manufacturer · 2022-06-01 — Company announcement of poster 816-P; the CEO describes the goal as "a cell-based therapy that doesn't require chronic immune suppression".
  5. [5]Pipeline of Bioprinted Tissue Therapeutics — Aspect Biosystems · manufacturer · 2026-07-14 — Accessed 15 July 2026. The type 1 diabetes programme ("stem cell islet clusters encapsulated within immune-protective materials") carries the development stage "Undisclosed"; the rare-endocrine (adrenal) programme is marked "Preclinical". No IND date or first-in-human timeline is given.
  6. [6]ClinicalTrials.gov sponsor query for Aspect Biosystems — no studies returned · registry · 2026-07-14 — Run 15 July 2026: the registry returns totalCount 0. Aspect Biosystems sponsors no registered clinical trial of any kind, in any indication.
  7. [7]Aspect wins $72.75m from Canadian government for bioprinted pipeline · news — Canadian government funding toward a $200m multi-year project to build clinical biomanufacturing capacity. Notes the Novo collaboration "has so far produced a preclinical pancreatic tissue candidate for type 1 diabetes".